Drupal.behaviors.print = function(context) {window.print();window.close();}>
SISCAPA-Based Biomarker Quantitation Moving to MALDI MS in Pursuit of Higher Throughput, Lower Costs
December 02, 2011
SISCAPA-Based Biomarker Quantitation Moving to MALDI MS in Pursuit of Higher Throughput, Lower Costs
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
New Instruments, Applications Powering Rise of MALDI-MS as Clinical Proteomics Platform
January 20, 2012 / ProteoMonitor
BRIMS-Led Study Suggests Clinical Viability of SRM-MS, Vendors' Role in Clinical Proteomics Process
June 8, 2012 / ProteoMonitor
Bruker, SISCAPA Assay Tech Study Suggests MALDI-MS Suitable for Clinical Protein Quantitation
January 30, 2012 / ProteoMonitor
At JP Morgan Mass Spec Vendors Highlight Clinical Efforts, Performance of High-Profile Releases
January 11, 2013 / ProteoMonitor
2012 Sees Rise of Targeted Proteomics and DIA-MS, Continued Clinical Push by Big Industry Players
January 4, 2013 / ProteoMonitor